Term,Overlap,P.value,Adjusted.P.value,Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
Fatty acid degradation,8/44,0.0013515484503978025,0.4162769227225232,0,0,3.6363636363636362,24.023652158325085,ACAA2;ADH1C;ALDH1B1;ACSL1;CYP4A11;HADH;ACADS;ADH5
"Valine, leucine and isoleucine degradation",7/48,0.009381035119053851,1,0,0,2.9166666666666665,13.618106740609136,ALDH6A1;ACAA2;ALDH1B1;OXCT1;HMGCS2;HADH;ACADS
Cytosolic DNA-sensing pathway,8/63,0.012855695577887951,1,0,0,2.5396825396825395,11.057697346558735,TBK1;CCL5;IL18;POLR2E;POLR3F;CGAS;POLR3K;POLR2K
Retinol metabolism,8/67,0.018203070712224476,1,0,0,2.388059701492537,9.566961143114478,UGT1A1;ADH1C;DHRS9;CYP4A11;UGT2B28;LRAT;CYP3A5;ADH5
Legionellosis,7/55,0.019161191353647928,1,0,0,2.545454545454545,10.066937565142911,BCL2L13;VCP;SAR1B;CASP3;RAB1B;IL18;TLR5
Drug metabolism,11/108,0.019216395842713684,0.9864416532593024,0,0,2.0370370370370368,8.05035288080842,RRM2;UGT1A1;GSTO2;ADH1C;GSTO1;UGT2B28;FMO1;MPO;CYP3A5;ADH5;NME1
Metabolism of xenobiotics by cytochrome P450,8/74,0.031098848162824908,1,0,0,2.1621621621621623,7.503966480103642,HSD11B1;UGT1A1;GSTO2;ADH1C;GSTO1;UGT2B28;CYP3A5;ADH5
Complement and coagulation cascades,8/79,0.043440838071242584,1,0,0,2.0253164556962022,6.35211202212957,C4A;F12;FGG;F11;C4BPA;F13B;F3;CFB
Butanoate metabolism,4/28,0.04895013769244342,1,0,0,2.8571428571428568,8.619865991683946,OXCT1;HMGCS2;HADH;ACADS
Chemical carcinogenesis,8/82,0.05220786888704381,1,0,0,1.951219512195122,5.7610186351061445,HSD11B1;UGT1A1;GSTO2;ADH1C;GSTO1;UGT2B28;CYP3A5;ADH5
Pantothenate and CoA biosynthesis,3/19,0.06645795649124922,1,0,0,3.157894736842105,8.561639256247336,VNN2;PPCDC;COASY
RNA polymerase,4/31,0.06697579978121662,1,0,0,2.5806451612903225,6.976577863571356,POLR2E;POLR3F;POLR3K;POLR2K
Viral myocarditis,6/59,0.073523209939382,1,0,0,2.0338983050847457,5.308788083641293,SGCD;CASP3;HLA-C;ABL2;SGCG;MYH6
Steroid hormone biosynthesis,6/60,0.07841676268446238,1,0,0,2,5.091435129458053,HSD11B1;UGT1A1;CYP11B2;UGT2B28;HSD17B7;CYP3A5
Pertussis,7/76,0.08519720761440963,1,0,0,1.8421052631578945,4.536712195036593,C4A;MAPK11;SFTPA2;CASP3;NLRP3;C4BPA;GNAI1
Synthesis and degradation of ketone bodies,2/10,0.08609691405925976,1,0,0,4,9.809126838186547,OXCT1;HMGCS2
Insulin resistance,9/108,0.09136126354936079,1,0,0,1.6666666666666665,3.9882228378768496,RPS6KA3;RPS6KA6;TBC1D4;NR1H2;MLX;PPP1R3A;PYGL;FOXO1;PCK2
Tyrosine metabolism,4/36,0.10349974906541197,1,0,0,2.222222222222222,5.040413535040945,PNMT;ADH1C;HGD;ADH5
Epithelial cell signaling in Helicobacter pylori infection,6/68,0.12385227423087532,1,0,0,1.7647058823529411,3.685880753701308,MAPK11;CASP3;CCL5;ATP6V0A2;TCIRG1;MAP3K14
alpha-Linolenic acid metabolism,3/25,0.1269942219814603,1,0,0,2.4,4.9526728554420085,FADS2;PLA2G12A;PLA2G4E
Non-homologous end-joining,2/13,0.13537899404817505,1,0,0,3.076923076923077,6.1528525246417765,PRKDC;POLL
Glutathione metabolism,5/56,0.14716977791840904,1,0,0,1.7857142857142856,3.4217292978951037,GCLC;RRM2;GSTO2;GSTO1;OPLAH
Ascorbate and aldarate metabolism,3/27,0.15038161447469178,1,0,0,2.222222222222222,4.210175820273459,ALDH1B1;UGT1A1;UGT2B28
Fatty acid elongation,3/27,0.15038161447469178,1,0,0,2.222222222222222,4.210175820273459,ACAA2;THEM4;HADH
Arrhythmogenic right ventricular cardiomyopathy (ARVC),6/72,0.15049803689681743,1,0,0,1.6666666666666665,3.1563420645887432,SGCD;ITGB8;CTNNA3;ITGB6;SGCG;DSC2
Tryptophan metabolism,4/42,0.1567023472093967,1,0,0,1.9047619047619047,3.5302993347271023,TPH1;ALDH1B1;KYNU;HADH
Inositol phosphate metabolism,6/74,0.1647057705275506,1,0,0,1.6216216216216217,2.924748009429989,ITPKB;ALDH6A1;INPP5F;INPP1;PIP5KL1;PLCH2
NOD-like receptor signaling pathway,12/178,0.18130858981611203,1,0,0,1.348314606741573,2.302321056168353,GSDMD;MAPK11;CASR;TBK1;NLRP7;CCL5;TRAF5;IL18;TXNIP;NLRP3;GBP2;TXN2
Cysteine and methionine metabolism,4/47,0.20718336704116536,1,0,0,1.7021276595744679,2.679406036964871,DNMT1;GCLC;TST;MTR
Base excision repair,3/33,0.22710442121127872,1,0,0,1.8181818181818181,2.695173385335862,NEIL3;MPG;POLL
Long-term potentiation,5/67,0.2431934021901658,1,0,0,1.4925373134328357,2.1102959080752326,GRIA1;RPS6KA3;RPS6KA6;CREBBP;GRIN1
Amyotrophic lateral sclerosis (ALS),4/51,0.2504443908625444,1,0,0,1.5686274509803921,2.171793530456325,GRIA1;MAPK11;CASP3;GRIN1
One carbon pool by folate,2/20,0.2641503607881601,1,0,0,2,2.66247357905395,DHFR;MTR
Lysosome,8/123,0.27337366492441967,1,0,0,1.3008130081300813,1.6870447917730367,ARSA;GGA1;GGA3;LAMP3;PSAP;ATP6V0A2;TCIRG1;MCOLN1
Protein digestion and absorption,6/90,0.29459151170537495,1,0,0,1.3333333333333333,1.6295541177562636,COL17A1;COL27A1;KCNE3;SLC7A9;XPNPEP2;COL11A1
Rheumatoid arthritis,6/91,0.303383440861158,1,0,0,1.3186813186813187,1.5728674181927342,CCL3L1;ANGPT1;CCL5;IL18;ATP6V0A2;TCIRG1
PPAR signaling pathway,5/74,0.31110059336369467,1,0,0,1.3513513513513513,1.577890496988918,FADS2;ACSL1;CYP4A11;HMGCS2;PCK2
Protein export,2/23,0.32060036735466374,1,0,0,1.7391304347826086,1.9783650312564471,SRP14;SRP9
Leukocyte transendothelial migration,7/112,0.3278524235285864,1,0,0,1.25,1.3939896251407393,MAPK11;MYL7;VCAM1;CLDN19;CLDN18;CTNNA3;GNAI1
Sulfur relay system,1/8,0.33662794865636386,1,0,0,2.5,2.721942421048515,TST
Vitamin digestion and absorption,2/24,0.33921547884608483,1,0,0,1.6666666666666665,1.8018662378583004,SLC5A6;LRAT
Lysine degradation,4/59,0.3411916398273588,1,0,0,1.3559322033898304,1.458048767361736,PRDM9;ALDH1B1;EHMT2;HADH
Glycerophospholipid metabolism,6/97,0.3569285827398046,1,0,0,1.2371134020618557,1.2744984316239885,PTDSS1;PLA2G12A;DGKB;PLA2G4E;CHAT;AGPAT1
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,2/25,0.3576694978288805,1,0,0,1.5999999999999999,1.645033455050064,PIGO;PIGW
Glycerolipid metabolism,4/61,0.36421006738242967,1,0,0,1.3114754098360655,1.3246222552325246,ALDH1B1;DGKB;LIPG;AGPAT1
Sulfur metabolism,1/9,0.3698097706633484,1,0,0,2.222222222222222,2.2105923086622967,TST
Progesterone-mediated oocyte maturation,6/99,0.37495373657039877,1,0,0,1.2121212121212122,1.1890334906277922,RPS6KA3;MAPK11;RPS6KA6;SPDYE16;SPDYE6;GNAI1
Folate biosynthesis,2/26,0.3759320092394212,1,0,0,1.5384615384615385,1.5051491975911149,DHFR;TPH1
Human papillomavirus infection,18/330,0.386237671152228,1,0,0,1.0909090909090908,1.0377844043199245,CREBBP;HLA-C;FZD8;CHD4;LAMB1;RFNG;TCIRG1;FOXO1;THBS3;TBK1;HEY1;TBPL2;CASP3;ATP6V0A2;ITGB8;ITGB6;HES3;CSNK1A1L
Basal transcription factors,3/45,0.3924009183942127,1,0,0,1.3333333333333333,1.2472949477860094,TAF13;TBPL2;GTF2E2
Glycosphingolipid biosynthesis,3/45,0.3924009183942127,1,0,0,1.3333333333333333,1.2472949477860094,FUT5;ST8SIA1;ST6GALNAC3
Biosynthesis of unsaturated fatty acids,2/27,0.39397603610044213,1,0,0,1.4814814814814814,1.3799484349837585,FADS2;FADS1
Collecting duct acid secretion,2/27,0.39397603610044213,1,0,0,1.4814814814814814,1.3799484349837585,ATP6V0A2;TCIRG1
Mitophagy,4/65,0.41006047139933866,1,0,0,1.2307692307692308,1.0971700171589474,BNIP3L;BCL2L13;TBK1;FUNDC1
Phototransduction,2/28,0.4117777723443979,1,0,0,1.4285714285714284,1.2675306609542623,GUCA1A;CNGB1
Ether lipid metabolism,3/47,0.4196120451603213,1,0,0,1.276595744680851,1.1086272722292005,PLA2G12A;PLA2G4E;ENPP2
Toll-like receptor signaling pathway,6/104,0.4200266801120024,1,0,0,1.1538461538461537,1.0008888988224178,MAPK11;TBK1;CCL3L1;CCL5;LBP;TLR5
Hypertrophic cardiomyopathy (HCM),5/85,0.42118396120911705,1,0,0,1.176470588235294,1.0172771508801166,SGCD;ITGB8;ITGB6;SGCG;MYH6
Linoleic acid metabolism,2/29,0.42931633359945176,1,0,0,1.379310344827586,1.1662913895494167,PLA2G12A;PLA2G4E
Salmonella infection,5/86,0.4311336138274714,1,0,0,1.1627906976744184,0.9782991023729873,MAPK11;CCL3L1;IL18;LBP;TLR5
Notch signaling pathway,3/48,0.43306631871249,1,0,0,1.25,1.0460805021359667,NCOR2;CREBBP;RFNG
Glycolysis / Gluconeogenesis,4/68,0.44400267624141365,1,0,0,1.176470588235294,0.9552055164674429,ADH1C;ALDH1B1;ADH5;PCK2
Malaria,3/49,0.44640402063272916,1,0,0,1.2244897959183672,0.987588809585937,VCAM1;IL18;THBS3
Ovarian steroidogenesis,3/49,0.44640402063272916,1,0,0,1.2244897959183672,0.987588809585937,PLA2G4E;LHB;HSD17B7
Citrate cycle (TCA cycle),2/30,0.44657352514826887,1,0,0,1.3333333333333333,1.0748682963163632,SUCLG1;PCK2
Cholesterol metabolism,3/50,0.4596144044474325,1,0,0,1.2,0.9328408706750739,LIPG;PCSK9;LPA
beta-Alanine metabolism,2/31,0.46353362563600886,1,0,0,1.2903225806451613,0.9920985153401862,ALDH6A1;ALDH1B1
TNF signaling pathway,6/110,0.4734883847029237,1,0,0,1.0909090909090908,0.8155940698683591,MAPK11;VCAM1;CASP3;CCL5;TRAF5;MAP3K14
Propanoate metabolism,2/32,0.4801831856912929,1,0,0,1.25,0.9169845137852034,ALDH6A1;SUCLG1
Dilated cardiomyopathy (DCM),5/91,0.48023571472567267,1,0,0,1.0989010989010988,0.8060200255732013,SGCD;ITGB8;ITGB6;SGCG;MYH6
Fc gamma R-mediated phagocytosis,5/91,0.48023571472567267,1,0,0,1.0989010989010988,0.8060200255732013,MYO10;PLA2G4E;BIN1;ASAP3;WASF3
Fatty acid biosynthesis,1/13,0.48676267554205266,1,0,0,1.5384615384615385,1.107659375220991,ACSL1
Bile secretion,4/72,0.48826565745953704,1,0,0,1.111111111111111,0.7965507124555724,AQP8;AQP4;SLC51A;SLC9A1
p53 signaling pathway,4/72,0.48826565745953704,1,0,0,1.111111111111111,0.7965507124555724,RRM2;CD82;SIVA1;CASP3
Vascular smooth muscle contraction,7/132,0.49185149962456454,1,0,0,1.0606060606060606,0.7525831919041477,PLA2G12A;KCNU1;CALCB;AVPR1B;PLA2G4E;CYP4A11;ACTG2
IL-17 signaling pathway,5/93,0.4994819883860412,1,0,0,1.075268817204301,0.7464341299256831,USP25;MAPK11;TBK1;CASP3;TRAF5
Serotonergic synapse,6/113,0.4997075653239782,1,0,0,1.0619469026548671,0.7367067833785346,HTR6;TPH1;PLA2G4E;CASP3;HTR1A;GNAI1
Pentose and glucuronate interconversions,2/34,0.5125071338352726,1,0,0,1.176470588235294,0.7864007628092599,UGT1A1;UGT2B28
Thyroid hormone signaling pathway,6/116,0.5254581276778527,1,0,0,1.0344827586206895,0.6656739028524064,CREBBP;HDAC3;TBC1D4;FOXO1;MYH6;SLC9A1
Insulin signaling pathway,7/137,0.5314567341654012,1,0,0,1.021897810218978,0.645975826925556,PRKAR2A;FLOT1;PPP1R3A;PYGL;EIF4E;FOXO1;PCK2
MicroRNAs in cancer,15/299,0.5324421113102931,1,0,0,1.0033444816053512,0.6323890620024301,CREBBP;DNMT1;MIR520E;MIR29C;MIR206;MIRLET7E;MIR203A;MIR215;ZEB2;MIR16-1;MIR375;CASP3;SPRY2;MIR128-2;MIR181A2
Pyrimidine metabolism,3/57,0.5477812798713707,1,0,0,1.0526315789473684,0.6335570484502631,CANT1;RRM2;NME1
Olfactory transduction,22/444,0.5489292037258071,1,0,0,0.990990990990991,0.594382325067679,OR8I2;OR1D2;OR10J5;OR2G3;OR10H2;OR5J2;OR2F1;OR52E2;OR1J4;OR2L3;OR8S1;OR2T6;OR2T11;OR5H15;OR2T2;OR13C9;OR52R1;OR8B3;OR4C11;OR4F6;OR52A5;CNGB1
Viral carcinogenesis,10/201,0.5523179780186385,1,0,0,0.9950248756218906,0.5906779616132228,CREBBP;EGR2;HDAC3;TBPL2;CASP3;TRAF5;HLA-C;CHD4;IL6ST;GTF2E2
Phosphatidylinositol signaling system,5/99,0.5554224977737025,1,0,0,1.01010101010101,0.5939658561566864,ITPKB;PIP4P2;INPP5F;DGKB;INPP1
African trypanosomiasis,2/37,0.5584386214472209,1,0,0,1.0810810810810811,0.62984925993825025,VCAM1;IL18
RNA degradation,4/79,0.561890006637219,1,0,0,1.0126582278481011,0.5837459908567373,BTG3;LSM7;DIS3L;XRN2
AGE-RAGE signaling pathway in diabetic complications,5/100,0.5644459548061124,1,0,0,1,0.5719106399118082,MAPK11;VCAM1;CASP3;F3;FOXO1
Ribosome biogenesis in eukaryotes,5/101,0.5733754172932677,1,0,0,0.9900990099009901,0.5507075230503586,NXF3;POP1;XRN2;DROSHA;WDR43
Nitrogen metabolism,1/17,0.5820286217003197,1,0,0,1.176470588235294,0.6367478285654856,CA3
Phenylalanine metabolism,1/17,0.5820286217003197,1,0,0,1.176470588235294,0.6367478285654856,GLYAT
Primary bile acid biosynthesis,1/17,0.5820286217003197,1,0,0,1.176470588235294,0.6367478285654856,CYP46A1
Selenocompound metabolism,1/17,0.5820286217003197,1,0,0,1.176470588235294,0.6367478285654856,MTR
Long-term depression,3/60,0.5828910435264506,1,0,0,1,0.5397549994176116,GRIA1;PLA2G4E;GNAI1
Pyruvate metabolism,2/39,0.5873014514915549,1,0,0,1.0256410256410255,0.5458636358886607,ALDH1B1;PCK2
ECM-receptor interaction,4/82,0.591620653904691,1,0,0,0.975609756097561,0.5120874505494942,ITGB8;LAMB1;ITGB6;THBS3
Ferroptosis,2/40,0.60119891797304,1,0,0,1,0.5088294208836465,GCLC;ACSL1
Nicotine addiction,2/40,0.60119891797304,1,0,0,1,0.5088294208836465,GRIA1;GRIN1
Fat digestion and absorption,2/41,0.6147400385913487,1,0,0,0.975609756097561,0.47468858733322344,PLA2G12A;AGPAT1
Arachidonic acid metabolism,3/63,0.6162178817161523,1,0,0,0.9523809523809523,0.4610996894309503,PLA2G12A;PLA2G4E;CYP4A11
cAMP signaling pathway,10/212,0.6203155438584437,1,0,0,0.9433962264150944,0.4504971591535261,GRIA1;GABBR2;HTR6;CREBBP;GPR119;HTR1A;GNAI1;GRIN1;SLC9A1;CNGB1
Steroid biosynthesis,1/19,0.6228154838888618,1,0,0,1.0526315789473684,0.4984262922061619,HSD17B7
Influenza A,8/171,0.6268081564909365,1,0,0,0.935672514619883,0.4370664380599916,MAPK11;CREBBP;TBK1;NXF3;CCL5;IL18;NLRP3;FURIN
Porphyrin and chlorophyll metabolism,2/42,0.6279256694973029,1,0,0,0.9523809523809523,0.4431747430401906,UGT1A1;UGT2B28
Type I diabetes mellitus,2/43,0.6407574714002146,1,0,0,0.9302325581395349,0.41405046828616976,PTPRN2;HLA-C
Phagosome,7/152,0.6417021441357289,1,0,0,0.9210526315789472,0.4086075302976567,RAB5B;SFTPA2;ATP6V0A2;HLA-C;TCIRG1;MPO;THBS3
Ribosome,7/153,0.6484975480312875,1,0,0,0.915032679738562,0.3962979599377591,RPL4;MRPL20;RPS9;RPL32;RPL21;RPL36;MRPS5
FoxO signaling pathway,6/132,0.6519118466202043,1,0,0,0.9090909090909091,0.3889508461515316,MAPK11;CREBBP;FBXO32;SGK1;FOXO1;PCK2
Vasopressin-regulated water reabsorption,2/44,0.6532378269725155,1,0,0,0.9090909090909091,0.38710364483347576,RAB5B;AQP4
GABAergic synapse,4/89,0.6561310542796738,1,0,0,0.898876404494382,0.3787817816859613,GABBR2;SLC12A5;GNAI1;SLC38A5
TGF-beta signaling pathway,4/90,0.6647641861492688,1,0,0,0.8888888888888888,0.362953696452133,CREBBP;TGIF2;INHBB;BMP7
ABC transporters,2/45,0.665369764985953,1,0,0,0.8888888888888888,0.3621443158089169,ABCB7;ABCC8
Staphylococcus aureus infection,3/68,0.6676380497864279,1,0,0,0.8823529411764706,0.3564786122927678,C4A;FGG;CFB
Other types of O-glycan biosynthesis,1/22,0.6766623505215513,1,0,0,0.9090909090909091,0.3550753401584873,RFNG
Terpenoid backbone biosynthesis,1/22,0.6766623505215513,1,0,0,0.9090909090909091,0.3550753401584873,HMGCS2
Tuberculosis,8/179,0.677184898085746,1,0,0,0.8938547486033519,0.34843435038653225,MAPK11;RAB5B;CREBBP;CASP3;ATP6V0A2;IL18;TCIRG1;LBP
Glutamatergic synapse,5/114,0.6799176333026349,1,0,0,0.8771929824561403,0.3384066803900328,GRIA1;GRM4;PLA2G4E;GNAI1;GRIN1
RIG-I-like receptor signaling pathway,3/70,0.6867423738774998,1,0,0,0.8571428571428571,0.32211090747805676,MAPK11;TBK1;TBKBP1
Nucleotide excision repair,2/47,0.6886033156551076,1,0,0,0.8510638297872339,0.3175233302317852,RFC2;RAD23B
Sphingolipid metabolism,2/47,0.6886033156551076,1,0,0,0.8510638297872339,0.3175233302317852,ARSA;SGPL1
Histidine metabolism,1/23,0.6928469690097347,1,0,0,0.8695652173913043,0.31908358966713624,ALDH1B1
Mismatch repair,1/23,0.6928469690097347,1,0,0,0.8695652173913043,0.31908358966713624,RFC2
Proximal tubule bicarbonate reclamation,1/23,0.6928469690097347,1,0,0,0.8695652173913043,0.31908358966713624,PCK2
Human cytomegalovirus infection,10/225,0.6932935578880997,1,0,0,0.8888888888888888,0.32560156891656883,AKAP13;MAPK11;TBK1;CCL3L1;CASP3;CCL5;TRAF5;HLA-C;CGAS;GNAI1
Amino sugar and nucleotide sugar metabolism,2/48,0.6997136081858564,1,0,0,0.8333333333333333,0.29757013234898655,FPGT;UAP1L1
Intestinal immune network for IgA production,2/48,0.6997136081858564,1,0,0,0.8333333333333333,0.29757013234898655,MAP3K14;CCR10
Fluid shear stress and atherosclerosis,6/139,0.7002204199629493,1,0,0,0.8633093525179856,0.30764901396557814,MAPK11;VCAM1;GSTO2;GSTO1;GPC1;TXN2
Adherens junction,3/72,0.7050123870135998,1,0,0,0.8333333333333333,0.2912832550768055,CREBBP;CTNNA3;WASF3
NF-kappa B signaling pathway,4/95,0.7056844804748206,1,0,0,0.8421052631578947,0.2935469919093557,VCAM1;TRAF5;LBP;MAP3K14
Arginine and proline metabolism,2/49,0.7104927276749392,1,0,0,0.8163265306122448,0.2790176057147895,ALDH1B1;CKM
Cocaine addiction,2/49,0.7104927276749392,1,0,0,0.8163265306122448,0.2790176057147895,GNAI1;GRIN1
Neuroactive ligand-receptor interaction,15/338,0.7191815436088637,1,0,0,0.8875739644970413,0.29258117622280166,GRIA1;GABBR2;CHRNB3;CALCB;AVPR1B;LHB;HTR1A;GRIN1;GHRHR;HTR6;GRM4;ADRB3;NPBWR2;DRD3;DRD4
N-Glycan biosynthesis,2/50,0.7209459791839935,1,0,0,0.7999999999999999,0.2617528554824198,MGAT4A;MGAT4B
Vibrio cholerae infection,2/50,0.7209459791839935,1,0,0,0.7999999999999999,0.2617528554824198,ATP6V0A2;TCIRG1
Circadian entrainment,4/97,0.7210011321847114,1,0,0,0.8247422680412371,0.269785213526288,GRIA1;CACNA1H;GNAI1;GRIN1
RNA transport,7/165,0.7238641717074015,1,0,0,0.8484848484848485,0.2741891619820413,POM121L2;EIF2B2;NXF3;POP1;TPR;EIF3F;EIF4E
Ras signaling pathway,10/232,0.7287862614859804,1,0,0,0.8620689655172414,0.2727368828310504,RAB5B;PLA2G12A;TBK1;RASA4B;ANGPT1;PLA2G4E;RASA1;ABL2;GRIN1;RASGRP3
Gastric acid secretion,3/75,0.7308710279969972,1,0,0,0.7999999999999999,0.2508146136696121,SLC26A7;GNAI1;SLC9A1
Choline metabolism in cancer,4/99,0.7357196016371502,1,0,0,0.8080808080808081,0.24800501727640314,SLC5A7;DGKB;PLA2G4E;WASF3
Cell adhesion molecules (CAMs),6/145,0.7378766133412128,1,0,0,0.8275862068965517,0.25156854534135115,VCAM1;CLDN19;HLA-C;ITGB8;CLDN18;NRXN2
Inflammatory mediator regulation of TRP channels,4/100,0.7428559954663433,1,0,0,0.7999999999999999,0.23780245442692988,MAPK11;TRPA1;PLA2G4E;CYP4A11
Antigen processing and presentation,3/77,0.7470972136000291,1,0,0,0.7792207792207791,0.22718958204818146,KIR2DS1;HLA-C;KIR2DL4
Platelet activation,5/124,0.7487088303457675,1,0,0,0.8064516129032258,0.23339122223979591,MAPK11;PLA2G4E;FGG;TLN1;GNAI1
Autoimmune thyroid disease,2/53,0.7504077852742062,1,0,0,0.7547169811320754,0.21670830680118947,TG;HLA-C
Huntington disease,8/193,0.7546266204717633,1,0,0,0.8290155440414507,0.23339456537289388,CREBBP;ATP5PD;DNAH2;TBPL2;CASP3;POLR2E;POLR2K;GRIN1
Chagas disease (American trypanosomiasis),4/103,0.7633839575456066,1,0,0,0.7766990291262135,0.20970419679401037,MAPK11;CCL3L1;CCL5;GNAI1
Glucagon signaling pathway,4/103,0.7633839575456066,1,0,0,0.7766990291262135,0.20970419679401037,CREBBP;PYGL;FOXO1;PCK2
Pathogenic Escherichia coli infection,2/55,0.7685284162153218,1,0,0,0.7272727272727272,0.1914747203489268,CTTN;TLR5
Regulation of lipolysis in adipocytes,2/55,0.7685284162153218,1,0,0,0.7272727272727272,0.1914747203489268,ADRB3;GNAI1
C-type lectin receptor signaling pathway,4/104,0.7699363530876122,1,0,0,0.7692307692307693,0.20111340452197826,MAPK11;EGR2;NLRP3;MAP3K14
Endocytosis,10/244,0.7830666966457429,1,0,0,0.8196721311475409,0.20044049648990897,RAB5B;DAB2;ACAP1;BIN1;DNAJC6;PIP5KL1;ASAP3;HLA-C;STAMBP;FOLR2
Th17 cell differentiation,4/107,0.7887401751709202,1,0,0,0.747663551401869,0.1774342589951246,MAPK11;RARA;IL6ST;IL27RA
Dopaminergic synapse,5/131,0.7899190896828266,1,0,0,0.7633587786259541,0.18001889838867802,GRIA1;MAPK11;DRD3;DRD4;GNAI1
Taste transduction,3/83,0.7911013287526669,1,0,0,0.7228915662650601,0.1693946149369998,GABBR2;GRM4;HTR1A
Epstein-Barr virus infection,8/201,0.7925273344506804,1,0,0,0.7960199004975124,0.18509714022296506,NCOR2;SEM1;MAPK11;TBK1;CASP3;TRAF5;HLA-C;MAP3K14
Circadian rhythm,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,BHLHE41
Galactose metabolism,1/31,0.7963417210162199,1,0,0,0.6451612903225806,0.1469205725810339,LCT
VEGF signaling pathway,2/59,0.8013529002820844,1,0,0,0.6779661016949152,0.15013820630777816,MAPK11;PLA2G4E
Axon guidance,7/181,0.8059436404362745,1,0,0,0.7734806629834253,0.1668718505593194,RASA1;SEMA3E;SEMA3F;EPHA1;BMP7;NTN1;GNAI1
Insulin secretion,3/86,0.8106028254070419,1,0,0,0.6976744186046511,0.14649563666446674,KCNU1;ABCC8;GPR119
Fructose and mannose metabolism,1/33,0.8162287694193023,1,0,0,0.6060606060606061,0.12306703553305594,FPGT
Estrogen signaling pathway,5/137,0.8208780761188903,1,0,0,0.72992700729927,0.14407349424250715,GABBR2;KRT14;RARA;KRT31;GNAI1
Thermogenesis,9/231,0.8216274337473796,1,0,0,0.7792207792207791,0.15309212749731324,RPS6KA3;MAPK11;RPS6KA6;ATP5PD;NDUFAF6;ADRB3;COX16;ACSL1;ARID1A
Toxoplasmosis,4/113,0.8226434279131911,1,0,0,0.7079646017699115,0.13821765033879096,MAPK11;CASP3;LAMB1;GNAI1
Transcriptional misregulation in cancer,7/186,0.8273600898825334,1,0,0,0.7526881720430108,0.1426458959005734,ETV7;EYA1;BMP2K;RARA;MPO;ETV4;FOXO1
Signaling pathways regulating pluripotency of stem cells,5/139,0.8303434515247903,1,0,0,0.7194244604316546,0.13375242213240954,MAPK11;FZD8;INHBB;IL6ST;ISL1
Prion diseases,1/35,0.8341755971925006,1,0,0,0.5714285714285714,0.103606486053202,CCL5
Calcium signaling pathway,7/188,0.8353889283325726,1,0,0,0.7446808510638298,0.13393671925321257,ITPKB;HTR6;AVPR1B;ADRB3;CACNA1H;GRIN1;TPCN1
DNA replication,1/36,0.8424812699182175,1,0,0,0.5555555555555555,0.09522436030767889,RFC2
Starch and sucrose metabolism,1/36,0.8424812699182175,1,0,0,0.5555555555555555,0.09522436030767889,PYGL
Inflammatory bowel disease (IBD),2/65,0.8428493095437481,1,0,0,0.6153846153846154,0.10521051812214251,IL18;TLR5
Shigellosis,2/65,0.8428493095437481,1,0,0,0.6153846153846154,0.10521051812214251,MAPK11;CTTN
Parkinson disease,5/142,0.8437741668121552,1,0,0,0.704225352112676,0.11962703877312425,ATP5PD;CASP3;HTRA2;GNAI1;SNCA
Acute myeloid leukemia,2/66,0.8489478345965421,1,0,0,0.6060606060606061,0.09924699267132996,RARA;MPO
GnRH signaling pathway,3/93,0.8501804853980194,1,0,0,0.6451612903225806,0.10471394598415903,MAPK11;PLA2G4E;LHB
Small cell lung cancer,3/93,0.8501804853980194,1,0,0,0.6451612903225806,0.10471394598415903,CASP3;TRAF5;LAMB1
Aldosterone-regulated sodium reabsorption,1/37,0.8503713249208762,1,0,0,0.5405405405405406,0.08761198488762709,SGK1
Thyroid cancer,1/37,0.8503713249208762,1,0,0,0.5405405405405406,0.08761198488762709,TPR
Hepatocellular carcinoma,6/168,0.8506043343825483,1,0,0,0.7142857142857142,0.11557728607067765,PHF10;GSTO2;GSTO1;FZD8;ARID1A;CSNK1A1L
Neurotrophin signaling pathway,4/119,0.851921877903696,1,0,0,0.6722689075630252,0.10773811694664917,RPS6KA3;MAPK11;RPS6KA6;MAGED1
Adrenergic signaling in cardiomyocytes,5/145,0.8563159481665291,1,0,0,0.689655172413793,0.10697646387244193,MAPK11;SCN1B;MYH6;GNAI1;SLC9A1
Allograft rejection,1/38,0.8578665401729517,1,0,0,0.5263157894736842,0.08068775746154062,HLA-C
Amphetamine addiction,2/68,0.860502636162266,1,0,0,0.588235294117647,0.08837564694787858,GRIA1;GRIN1
Fc epsilon RI signaling pathway,2/68,0.860502636162266,1,0,0,0.588235294117647,0.08837564694787858,MAPK11;PLA2G4E
Amoebiasis,3/96,0.8648106182658194,1,0,0,0.625,0.09077795902611915,RAB5B;CASP3;LAMB1
Adipocytokine signaling pathway,2/69,0.8659715129706728,1,0,0,0.5797101449275363,0.08342218313842696,ACSL1;PCK2
Renin secretion,2/69,0.8659715129706728,1,0,0,0.5797101449275363,0.08342218313842696,ADRB3;GNAI1
Phospholipase D signaling pathway,5/148,0.8680063003348341,1,0,0,0.6756756756756757,0.09564615263368895,GRM4;AVPR1B;DGKB;PLA2G4E;AGPAT1
Prolactin signaling pathway,2/70,0.8712429450339811,1,0,0,0.5714285714285714,0.0787625225498065,MAPK11;LHB
"Glycine, serine and threonine metabolism",1/40,0.8717504251826977,1,0,0,0.5,0.06862605284591321,GCAT
Cytokine-cytokine receptor interaction,11/294,0.8744398369200312,1,0,0,0.7482993197278911,0.10040065470018435,CX3CR1;CCL3L1;IL7;CCL5;IL18;INHBB;IL6ST;BMP7;CCR10;IL27RA;TNFRSF10D
Oocyte meiosis,4/125,0.8769959948339774,1,0,0,0.64,0.08400182624919345,RPS6KA3;RPS6KA6;SPDYE16;SPDYE6
Graft-versus-host disease,1/41,0.878175666331951,1,0,0,0.4878048780487805,0.0633700633222169,HLA-C
Homologous recombination,1/41,0.878175666331951,1,0,0,0.4878048780487805,0.0633700633222169,SEM1
Proteoglycans in cancer,7/201,0.8805619416668193,1,0,0,0.6965174129353233,0.08859353598323239,MAPK11;CTTN;GPC1;CASP3;FZD8;DROSHA;SLC9A1
mTOR signaling pathway,5/152,0.8823360987788662,1,0,0,0.6578947368421052,0.08235673104394964,RPS6KA3;RPS6KA6;FZD8;SGK1;EIF4E
HIF-1 signaling pathway,3/100,0.8823533306415342,1,0,0,0.6,0.07509762093621879,CREBBP;ANGPT1;EIF4E
Melanogenesis,3/101,0.8864097011888528,1,0,0,0.594059405940594,0.07162931796059352,CREBBP;FZD8;GNAI1
Longevity regulating pathway,3/102,0.8903406760313634,1,0,0,0.588235294117647,0.06832418084741279,EHMT2;EIF4E;FOXO1
Bacterial invasion of epithelial cells,2/74,0.8904734986911036,1,0,0,0.5405405405405406,0.06270374958254536,CTTN;CTNNA3
Thyroid hormone synthesis,2/74,0.8904734986911036,1,0,0,0.5405405405405406,0.06270374958254536,TG;SERPINA7
Purine metabolism,4/129,0.8915945370687862,1,0,0,0.6201550387596899,0.07115894858860422,CANT1;RRM2;HDDC3;NME1
Carbohydrate digestion and absorption,1/44,0.8955853061573006,1,0,0,0.45454545454545453,0.05012627322480098,LCT
Natural killer cell mediated cytotoxicity,4/131,0.8983079302400212,1,0,0,0.6106870229007633,0.06549151922621713,KIR2DS1;CASP3;HLA-C;KIR2DL4
Proteasome,1/45,0.9008174591944802,1,0,0,0.4444444444444444,0.046423395514619575,SEM1
"Parathyroid hormone synthesis, secretion and action",3/106,0.9048723287754362,1,0,0,0.5660377358490566,0.05658193494921566,AKAP13;CASR;GNAI1
Type II diabetes mellitus,1/46,0.9057876758651223,1,0,0,0.43478260869565216,0.04302189293649987,ABCC8
Cardiac muscle contraction,2/78,0.9070080241695482,1,0,0,0.5128205128205128,0.0500533240880421,MYH6;SLC9A1
Synaptic vesicle cycle,2/78,0.9070080241695482,1,0,0,0.5128205128205128,0.0500533240880421,ATP6V0A2;TCIRG1
Kaposi sarcoma-associated herpesvirus infection,6/186,0.9081344372566347,1,0,0,0.6451612903225806,0.06216958237920191,MAPK11;CREBBP;TBK1;CASP3;HLA-C;IL6ST
Human immunodeficiency virus 1 infection,7/212,0.9102489016760925,1,0,0,0.660377358490566,0.06210003677512062,MAPK11;TBK1;CASP3;TRAF5;HLA-C;CGAS;GNAI1
Hedgehog signaling pathway,1/47,0.9105090567783704,1,0,0,0.42553191489361697,0.03989422673431822,CSNK1A1L
Hepatitis B,5/163,0.9150605393003802,1,0,0,0.6134969325153374,0.05445708756164863,MAPK11;CREBBP;EGR2;TBK1;CASP3
Ubiquitin mediated proteolysis,4/137,0.9162983017532836,1,0,0,0.583941605839416,0.05104426883901789,HERC2;UBE2Q2;UBE2NL;UBE2M
Measles,4/138,0.9190038309457114,1,0,0,0.5797101449275363,0.0489652104536948,TBK1;CASP3;RAB9B;SLAMF1
Protein processing in endoplasmic reticulum,5/165,0.9200650455836688,1,0,0,0.6060606060606061,0.05049146043449751,VCP;SEC24A;SAR1B;FBXO6;RAD23B
Cholinergic synapse,3/112,0.9234195962447295,1,0,0,0.5357142857142857,0.04268118605193645,SLC5A7;CHAT;GNAI1
Peroxisome,2/83,0.9243958207118659,1,0,0,0.4819277108433735,0.03788670924051055,ACSL1;CRAT
Human T-cell leukemia virus 1 infection,7/219,0.925646181774397,1,0,0,0.639269406392694,0.04939200669208585,CREBBP;EGR2;MSX2;TBPL2;HLA-C;TLN1;MAP3K14
Mineral absorption,1/51,0.9271460027962314,1,0,0,0.39215686274509803,0.029664402156312095,MT1HL1
MAPK signaling pathway,10/295,0.9282751917651898,1,0,0,0.6779661016949152,0.05045901512247933,RPS6KA3;MAPK11;RPS6KA6;ANGPT1;PLA2G4E;CASP3;RASA1;MAP3K14;CACNA1H;RASGRP3
Apoptosis,4/143,0.931389987367667,1,0,0,0.5594405594405594,0.039763467737085244,CASP3;HTRA2;MAP3K14;SPTAN1
Glycosaminoglycan biosynthesis,1/53,0.9342669389173686,1,0,0,0.3773584905660377,0.02565776594269266,XYLT1
Focal adhesion,6/199,0.9367347778999319,1,0,0,0.6030150753768844,0.03941010533489616,MYL7;ITGB8;LAMB1;ITGB6;TLN1;THBS3
Fanconi anemia pathway,1/54,0.9375622230779963,1,0,0,0.37037037037037035,0.02387857483587084,SLX1A
Sphingolipid signaling pathway,3/119,0.9408414997698965,1,0,0,0.5042016806722689,0.030746516803698005,MAPK11;SGPL1;GNAI1
Salivary secretion,2/90,0.9436483877912323,1,0,0,0.4444444444444444,0.025778512347182387,ADRB3;SLC9A1
Morphine addiction,2/91,0.9459848142593618,1,0,0,0.43956043956043955,0.024408247313871943,GABBR2;GNAI1
mRNA surveillance pathway,2/91,0.9459848142593618,1,0,0,0.43956043956043955,0.024408247313871943,NXF3;SMG6
Rap1 signaling pathway,6/206,0.9485996027828901,1,0,0,0.5825242718446602,0.030738922881033786,MAPK11;ANGPT1;TLN1;GNAI1;GRIN1;RASGRP3
Endometrial cancer,1/58,0.9491734416512021,1,0,0,0.3448275862068965,0.017987494665677846,CTNNA3
Cushing syndrome,4/155,0.954421312324339,1,0,0,0.5161290322580645,0.024077459534487835,WDR5B;FZD8;CACNA1H;GNAI1
Hepatitis C,4/155,0.954421312324339,1,0,0,0.5161290322580645,0.024077459534487835,TBK1;CASP3;CLDN19;CLDN18
Prostate cancer,2/97,0.9581767039032599,1,0,0,0.41237113402061853,0.017617759662583495,CREBBP;FOXO1
Wnt signaling pathway,4/158,0.9589416360981469,1,0,0,0.5063291139240506,0.021227881051499004,CREBBP;TBL1XR1;FZD8;CSNK1A1L
Aldosterone synthesis and secretion,2/98,0.9599334606764933,1,0,0,0.4081632653061224,0.01669033008887676,CYP11B2;CACNA1H
Pancreatic secretion,2/98,0.9599334606764933,1,0,0,0.4081632653061224,0.01669033008887676,PLA2G12A;SLC9A1
Basal cell carcinoma,1/63,0.9607020222041087,1,0,0,0.31746031746031744,0.012727297981234762,FZD8
Cellular senescence,4/160,0.9617208990739988,1,0,0,0.5,0.019515498056869092,MAPK11;HLA-C;FOXO1;KIR2DL4
Chemokine signaling pathway,5/190,0.9638364264942945,1,0,0,0.5263157894736842,0.01938614780477967,CX3CR1;CCL3L1;CCL5;CCR10;GNAI1
JAK-STAT signaling pathway,4/162,0.9643248581685346,1,0,0,0.49382716049382713,0.01793928461161327,CREBBP;IL7;IL6ST;IL27RA
Necroptosis,4/162,0.9643248581685346,1,0,0,0.49382716049382713,0.01793928461161327,PLA2G4E;TRAF5;NLRP3;PYGL
Cortisol synthesis and secretion,1/65,0.9645452489317999,1,0,0,0.3076923076923077,0.011107241028940524,CACNA1H
T cell receptor signaling pathway,2/101,0.9647890418591292,1,0,0,0.396039603960396,0.014196360797659355,MAPK11;MAP3K14
Oxidative phosphorylation,3/133,0.9652081031256262,1,0,0,0.45112781954887216,0.015975135331615462,ATP5PD;ATP6V0A2;TCIRG1
Aminoacyl-tRNA biosynthesis,1/66,0.9663236546235302,1,0,0,0.30303030303030304,0.010380743845736572,AARS2
cGMP-PKG signaling pathway,4/166,0.9690459398300972,1,0,0,0.4819277108433735,0.01515337768182299,KCNU1;ADRB3;GNAI1;CNGB1
PI3K-Akt signaling pathway,11/354,0.9691876884305263,1,0,0,0.6214689265536724,0.019450108604704537,ANGPT1;IL7;MTCP1;THEM4;ITGB8;LAMB1;ITGB6;SGK1;EIF4E;PCK2;THBS3
Renal cell carcinoma,1/69,0.9711417402987961,1,0,0,0.2898550724637681,0.00848778197469868,CREBBP
Tight junction,4/170,0.9731786220354677,1,0,0,0.47058823529411764,0.012794181169583136,CTTN;CLDN19;CLDN18;AMOTL1
B cell receptor signaling pathway,1/71,0.9739647545480367,1,0,0,0.28169014084507044,0.00743103163098366,RASGRP3
Alzheimer disease,4/171,0.9741278417674597,1,0,0,0.4678362573099415,0.012263265296528252,ATP5PD;CASP3;SNCA;GRIN1
Herpes simplex virus 1 infection,16/492,0.9774318453772831,1,0,0,0.6504065040650406,0.014846642570799519,ZNF790;EIF2B2;ZNF705D;HLA-C;CGAS;TBK1;NXF3;ZNF429;ZNF627;CCL5;CASP3;TRAF5;ZNF845;ZNF267;ZNF641;ZNF420
Leishmaniasis,1/74,0.9776904281936729,1,0,0,0.2702702702702703,0.00609789044447976,MAPK11
Breast cancer,3/147,0.9798793347088299,1,0,0,0.4081632653061224,0.008296262345513448,HEY1;FZD8;CSNK1A1L
Retrograde endocannabinoid signaling,3/148,0.9806622539772427,1,0,0,0.40540540540540543,0.007916418722549444,GRIA1;MAPK11;GNAI1
Alcoholism,4/180,0.9813594217944765,1,0,0,0.4444444444444444,0.008362890420356268,HDAC3;GNAI1;CAMKK1;GRIN1
Gastric cancer,3/149,0.981416039698096,1,0,0,0.40268456375838924,0.007553883933884644,FZD8;CTNNA3;CSNK1A1L
AMPK signaling pathway,2/120,0.9846775335112893,1,0,0,0.3333333333333333,0.005147022851847904,FOXO1;PCK2
Cell cycle,2/124,0.987173993434516,1,0,0,0.3225806451612903,0.004164183852806964,CREBBP;PRKDC
ErbB signaling pathway,1/85,0.987338361755133,1,0,0,0.23529411764705882,0.0029982305654579823,ABL2
Colorectal cancer,1/86,0.9879740196694372,1,0,0,0.23255813953488372,0.0028136924328252115,CASP3
Hippo signaling pathway,3/160,0.988053565127078,1,0,0,0.37499999999999994,0.004506887620583272,FZD8;CTNNA3;BMP7
Osteoclast differentiation,2/127,0.9887816352200313,1,0,0,0.31496062992125984,0.0035533118886497796,MAPK11;MAP3K14
Gap junction,1/88,0.9891512672040396,1,0,0,0.22727272727272727,0.002479093046554197,GNAI1
Autophagy,2/128,0.9892724806799553,1,0,0,0.3125,0.003370460625435029,WIPI2;ATG4D
Relaxin signaling pathway,2/130,0.9901920980145356,1,0,0,0.3076923076923077,0.0030327127009217966,MAPK11;GNAI1
Pathways in cancer,16/530,0.9909741044865876,1,0,0,0.6037735849056604,0.005474340035127803,CREBBP;GSTO2;GSTO1;FZD8;LAMB1;FOXO1;GNAI1;RASGRP3;HEY1;IL7;CASP3;TPR;TRAF5;RARA;CTNNA3;IL6ST
Th1 and Th2 cell differentiation,1/92,0.99117152080333,1,0,0,0.21739130434782608,0.00192775676491022,MAPK11
Spliceosome,2/134,0.9918061738095247,1,0,0,0.29850746268656714,0.002455994057658477,LSM7;PRPF8
Apelin signaling pathway,2/137,0.9928432555950474,1,0,0,0.291970802919708,0.002097073502741547,GNAI1;SLC9A1
Hematopoietic cell lineage,1/97,0.993176581718741,1,0,0,0.20618556701030927,0.001411712214835502,IL7
Regulation of actin cytoskeleton,4/214,0.9948630743128654,1,0,0,0.3738317757009345,0.0019252953454580114,MYL7;ITGB8;ITGB6;SLC9A1
Non-alcoholic fatty liver disease (NAFLD),2/149,0.9958502577635029,1,0,0,0.2684563758389262,0.0011163426338827505,CASP3;MLX
Oxytocin signaling pathway,2/153,0.9965438105731989,1,0,0,0.26143790849673204,9.051440122682747e-4,PLA2G4E;GNAI1
Systemic lupus erythematosus,1/133,0.99893267616922,1,0,0,0.15037593984962405,1.6058553781593565e-4,C4A
